Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857921 | 0.97 | ITGA4 (0.54) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3848814 | 0.95 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3854111 | 0.94 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3850110 | 0.94 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL4415981 | 0.93 | ITGA4 (0.50) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL4431680 | 0.92 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3858950 | 0.92 | ITGA4 (0.56) | ITGA4ITGB1ITGB7ITGA5MAPK1 | |
| SCHEMBL3851145 | 0.92 | ITGA4 (0.54) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3853214 | 0.92 | ITGA4 (0.52) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3849319 | 0.92 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1592386-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGA4 3/4885P2RX7 1115/4885CACNA1B 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.